| Literature DB >> 33007262 |
Galit Alter1, Wen-Han Yu1, Abishek Chandrashekar2, Erica N Borducchi2, Khader Ghneim3, Ashish Sharma3, Rebecca Nedellec4, Katherine R McKenney4, Caitlyn Linde1, Thomas Broge1, Todd J Suscovich1, Tom Linnekin1, Peter Abbink2, Noe B Mercado2, Joseph P Nkolola2, Katherine McMahan2, Esther A Bondzie2, Venous Hamza2, Lauren Peter2, Nicole Kordana2, Shant Mahrokhian2, Michael S Seaman2, Wenjun Li5, Mark G Lewis6, Douglas A Lauffenburger7, Lars Hangartner4, Rafick-Pierre Sekaly3, Dan H Barouch8.
Abstract
Several HIV-1 and SIV vaccine candidates have shown partial protection against viral challenges in rhesus macaques. However, the protective efficacy of vaccine-elicited polyclonal antibodies has not previously been demonstrated in adoptive transfer studies in nonhuman primates. In this study, we show that passive transfer of purified antibodies from vaccinated macaques can protect naive animals against SIVmac251 challenges. We vaccinated 30 rhesus macaques with Ad26-SIV Env/Gag/Pol and SIV Env gp140 protein vaccines and assessed the induction of antibody responses and a putative protective signature. This signature included multiple antibody functions and correlated with upregulation of interferon pathways in vaccinated animals. Adoptive transfer of purified immunoglobulin G (IgG) from the vaccinated animals with the most robust protective signatures provided partial protection against SIVmac251 challenges in naive recipient rhesus macaques. These data demonstrate the protective efficacy of purified vaccine-elicited antiviral antibodies in this model, even in the absence of virus neutralization.Entities:
Keywords: ADCC; Ad26; HIV; SIV; adoptive transfer; antibodies; systems biology; transcriptomics; vaccines
Mesh：
Substances：
Year: 2020 PMID： 33007262 PMCID： PMC7534693 DOI： 10.1016/j.cell.2020.08.033
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582